Das infantile Fibrosarkom (IFS) wird durch die ETV6-NTRK3-Fusion (> 90%) definiert. Larotrectinib hat eine...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-NTRK-FUSION-IFS |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-IFS |
| Quellen | SRC-CIVIC SRC-FDA-CDS-2026 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-NTRK-FUSION |
|---|---|
| Variante | Fusion ETV6-NTRK3 (Bestimmung der Läsion) |
| Erkrankung | DIS-IFS |
| ESCAT-Stufe | IA |
| Empfohlene Kombinationen | larotrectinib monotherapy (1L for unresectable / metastatic IFS — chemotherapy-sparing), entrectinib monotherapy |
| Kontraindizierte Monotherapie | VAC chemotherapy (vincristine/actinomycin/cyclophosphamide) as 1L when NTRK-TKI available — no longer standard given larotrectinib tolerability and efficacy |
| Zusammenfassung der Beweise | Infantile fibrosarcoma (IFS) is defined by ETV6-NTRK3 fusion (>90%). Larotrectinib has transformative activity (SCOUT pediatric trial, Laetsch Lancet Oncol 2018 — ORR 93% in IFS), enabling organ-sparing surgery and avoiding mutilating resection or intensive chemotherapy. Tumor-agnostic FDA approval since 2018; SCOUT data drove pediatric label. |
Anmerkungen
ESCAT IA. OncoKB Level 1. IFS is the prototype tumor for the paradigm shift from cytotoxic to targeted therapy in pediatric oncology. Prior standard (VAC chemotherapy) achieved ~70% response but with substantial toxicity. Larotrectinib enables less mutilating surgery in localized IFS. Source-gap: SRC-NCCN-PEDIATRIC-SARCOMA / SRC-SCOUT not yet ingested.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.